BioVie's stock is expected to face significant downward pressure due to the failure of its key drug, bezisterim, to meet primary endpoints in the overall Long COVID trial population. While some subgroup results were positive, the overall lack of statistical significance casts doubt on the drug's broad efficacy and commercial viability, leading to investor uncertainty.
This headline represents a major negative catalyst for BioVie. The failure of bezisterim to achieve statistical significance in its Phase 2 Long COVID trial's overall population is a significant setback, as it indicates the drug may not be broadly effective. While positive results in pre-specified subgroups offer a glimmer of hope, they are generally viewed with skepticism by the market as they can be a result of data mining. This outcome significantly reduces the drug's probability of successful development and commercialization, leading to a likely sharp decline in BioVie's stock price. Investors will be closely watching the September 15 call for further details and the company's path forward.